Ordaōs is a human-enabled, machine-driven drug design company that uses generative AI to design de novo mini-proteins and optimize single-domain antibodies for therapeutic discovery
Ordaōs is a human-enabled, machine-driven drug design company that uses generative AI to design de novo mini-proteins and optimize single-domain antibodies for therapeutic discovery. Its miniPRO proteins are developed through internal programs and partnerships with pharmaceutical and biotechnology companies, with a focus on configurable, stable, manufacturable candidates for unmet medical needs.